Rostock- Germany- October 1- 2007 / b3c newswire / - Bionas GmbH- a specialist for in vitro profiling of cellular metabolic activity- announced that it has signed a service contract with Solvay Pharmaceuticals GmbH (Hannover- Germany). The contract covers the metabolic profiling of several drug candidates identified in the context of Solvays obesity research program. Financial details were not disclosed.
Solvay has selected the Bionas 2500 analyzing system because itallows monitoring of both acute (short-term) and chronic(long-term) effects of drug candidates in different cell typesthanks to a proprietary perfusion system. Besides the long-termobservation of cells under close to in vivo conditions- theobservation of regeneration effects is also possible.